US Patent Issued to Regents of the University of Minnesota on Sept. 16 for "CD200AR ligands for cancer immunotherapy" (Minnesota Inventor)

ALEXANDRIA, Va., Sept. 17 -- United States Patent no. 12,414,983, issued on Sept. 16, was assigned to Regents of the University of Minnesota (Minneapolis).

"CD200AR ligands for cancer immunotherapy" was invented by Michael Olin (Minneapolis).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention in certain embodiments provides a method of inhibiting PD-1 in a cell by administering a CD200 activation receptor ligand (CD200AR-L) to the cell. The present invention in certain embodiments provides a method of enhancing efficacy of a tumor lysate vaccine in a mammal comprising administering a CD200 activation receptor ligand (CD200AR-L) to the mammal prior to the administration of the tumor lysate vac...